other material
confidence high
sentiment positive
materiality 0.75
Tonix adds Medicare Part D coverage for TONMYA, expanding access to 145M lives by Jan 2027
Tonix Pharmaceuticals Holding Corp.
- New Medicare agreement effective Jan 1, 2027 adds ~9M Medicare Part D lives (16% of U.S. Medicare).
- Combined with prior commercial GPO deals and Medicaid, TONMYA coverage reaches ~145M lives (46% of U.S. covered lives).
- Sales force to expand by 50 reps by mid-Q3 2026, total ~150 reps.
- TONMYA is a first-in-class, non-opioid sublingual cyclobenzaprine for fibromyalgia.
- Positive launch metrics cited: new prescribers, new patients, total and refill prescriptions.